SLRN FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit Stemming from Drug Candidate’s Progress
15 janv. 2024 15h04 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
SLRN 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit
10 janv. 2024 18h49 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
07 janv. 2024 10h50 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
SLRN 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit Stemming from Drug Candidate’s Progress
04 janv. 2024 15h01 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4,...
Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate’s Progress-Hagens Berman
01 janv. 2024 09h35 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
29 déc. 2023 13h50 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
22 déc. 2023 14h22 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress-Hagens Berman
18 déc. 2023 16h14 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
17 déc. 2023 08h01 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds Acelyrin investors of a class action lawsuit and upcoming deadline.
Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action -Hagens Berman
15 déc. 2023 16h34 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...